Proprioception in Parkinson's disease is acutely depressed by dopaminergic medications
- PMID: 11606670
- PMCID: PMC1737594
- DOI: 10.1136/jnnp.71.5.607
Proprioception in Parkinson's disease is acutely depressed by dopaminergic medications
Abstract
Objectives: Impaired proprioception has been previously reported in patients with Parkinson's disease. It was hypothesised that dopaminergic medications transiently depress proprioception, with amplification of adventitious movements as a result. This study tested for effects on proprioception of dopaminergic drugs, and for associations between such effects and drug induced dyskinesias.
Methods: In 17 patients with Parkinson's disease, arm proprioception was tested in the practically defined "off" state, and retested 1 hour after taking levodopa or dopamine agonist. Testing consisted of side to side comparison of elbow angle, matching the contralateral elbow angle, and spatial recall of an unrestrained arm.
Results: Proprioception deteriorated as hypothesised, reaching significance by one tailed t test for each of the three tasks. The relative deterioration (and the 95% lower confidence bound for estimated deterioration) was 31% (4%) for side to side elbow comparison, was 27% (11%) for accuracy in matching the contralateral elbow angle, and was 11% (0%) for spatial recall. Dyskinetic (n=6) and non-dyskinetic (n=11) patients did not differ significantly in these effects on proprioception. Control subjects (n=6) and untreated parkinsonian subjects (n=5) did not significantly differ from the parkinsonian patients in the off state.
Conclusions: Administration of levodopa and dopamine agonists were associated with a modest acute suppression in central responsiveness to joint position. It is speculated that compensatory exaggerated movement could account in part for the phenomenon of drug induced dyskinesias.
Similar articles
-
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.J Neurol Neurosurg Psychiatry. 1998 May;64(5):573-6. doi: 10.1136/jnnp.64.5.573. J Neurol Neurosurg Psychiatry. 1998. PMID: 9598668 Free PMC article.
-
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.CNS Drugs. 2004;18(11):733-46. doi: 10.2165/00023210-200418110-00003. CNS Drugs. 2004. PMID: 15330687 Clinical Trial.
-
Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.J Neurol. 2018 Sep;265(9):2088-2096. doi: 10.1007/s00415-018-8945-1. Epub 2018 Jul 6. J Neurol. 2018. PMID: 29980853
-
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.Eur Neurol. 2008;60(2):57-66. doi: 10.1159/000131893. Epub 2008 May 15. Eur Neurol. 2008. PMID: 18480609 Review.
-
Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.Expert Rev Neurother. 2015 Feb;15(2):207-13. doi: 10.1586/14737175.2015.1001747. Epub 2015 Jan 12. Expert Rev Neurother. 2015. PMID: 25578445 Review.
Cited by
-
Haptic perception of object curvature in Parkinson's disease.PLoS One. 2008 Jul 9;3(7):e2625. doi: 10.1371/journal.pone.0002625. PLoS One. 2008. PMID: 18612466 Free PMC article.
-
Proprioceptive recalibration following implicit visuomotor adaptation is preserved in Parkinson's disease.Exp Brain Res. 2021 May;239(5):1551-1565. doi: 10.1007/s00221-021-06075-y. Epub 2021 Mar 10. Exp Brain Res. 2021. PMID: 33688984
-
Sensory attenuation in Parkinson's disease is related to disease severity and dopamine dose.Sci Rep. 2018 Oct 23;8(1):15643. doi: 10.1038/s41598-018-33678-3. Sci Rep. 2018. PMID: 30353104 Free PMC article.
-
Reaching to proprioceptively defined targets in Parkinson's disease: effects of deep brain stimulation therapy.Neuroscience. 2013 Aug 6;244:99-112. doi: 10.1016/j.neuroscience.2013.04.009. Epub 2013 Apr 13. Neuroscience. 2013. PMID: 23590906 Free PMC article. Clinical Trial.
-
Effects of exercise induced oxidative stress on glutathione levels in Parkinson's disease on and off medication.J Neurol. 2010 Oct;257(10):1648-53. doi: 10.1007/s00415-010-5584-6. Epub 2010 May 12. J Neurol. 2010. PMID: 20461398
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical